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1. Introduction
Gene therapy is a novel approach that broadly defined as the transfer of genetic material into
a cell, tissue, or whole organ, with the goal of curing a disease or at least improving the clinical
status of a patient [1]. Gene therapy refers to local or systemic administration of a nucleic acid
construct that can prevent, treat and even cure diseases by changing the expression of genes
that are responsible for the pathological condition [2]. As a form of molecular medicine, gene
therapy hold great promises to provide new treatments for a large number of inherited and
acquired diseases, such as cancer. It has also been considered as suitable substitute for
conventional protein therapy, since it can overcome inherent problems associated with
administration of protein drugs in terms of bioavailability, systemic toxicity and manufactur‐
ing cost [3].
There are two essential components in current gene therapy: an effective therapeutic genetic
agent and the gene delivery system [4, 5]. The most extensively studied approach involves the
delivery of plasmid DNA (pDNA) for expressing therapeutic transgenes. Considerable efforts
have been made in plasmid design. This includes removal of extraneous CG dinucleotides,
incorporation of scaffold/matrix attached region sequences to prolong expression, promoter
selection for gene expression, and improving plasmid entry into the nucleus [6]. The recently
emerged RNA interference (RNAi) has also become recognized as pivotal cellular regulator of
genetic events and a useful tool in elucidating pathways during stages of development,
pathogenesis and senescent cell regulation [7]. RNAi encompasses the range of endogenous
or synthetic short double or single stranded oligonucleotides, including microRNAs (miR‐
NAs), small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs), piwi interacting RNAs
(piRNAs) and antisense oligonucleotides (ASOs) [8]. The intracellular delivery of genetic
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agents for RNAi such as siRNA takes benefits from existing expertise in pDNA transfer, as
they share common properties. However, they face distinct challenges due to apparent
differences in size, stability of the formed nucleic acid complexes, the location and mechanism
of action [9].
Naked genetic therapeutics is vulnerable to enzyme degradation, rapid clearance by renal
filtration, poor cellular uptake due to anionic charges of the phosphate backbone, inefficiently
escape from endosome into cytosol. Therefore, the development of gene vectors for effectively
carrying genes into cells has made a great deal of progress in recent years [5, 10]. Vectors as
gene delivery system that have been developed fall into two broad categories: viral and non-
viral vectors. Vectors based upon many different viral systems, including retroviruses,
lentiviruses, adenoviruses, and adeno-associated viruses (AAV) (Table 1), currently offer the
best choice for efficient gene delivery [11, 12]. They are all highly efficient in specific circum‐
stances, but the potential risks of undesired immune response and the risk of insertional
mutagenesis following long term viral gene transfer and toxic side reactions have raised
concerns [13-15].
Virus Genome Size Advantages Disadvantages
Retrovirus ssRNA 7-10 kb Long-term expression Application is limited to replicating cellsPossibility of insertional mutagenesis
Adenovirus dsDNA 36 kb
Capable of very efficient episomal
gene transfer in a wide range of
cells and tissues
Easy to grow in large amounts
The host response to the virus appears
to limit the duration of expression and
the ability to repeat dosing
AAV ssDNA 5 kb
Structurally simple
Provoke less of a host-cell
response
Extremely difficult to grow in large
amounts
Table 1. Viral vector delivery systems [12].
Although viral vector has the advantages in terms of gene transfer efficiency, non-viral gene
therapy has the advantage over viral vector therapies with its ability to target specific cells,
being less immunogenic and non-integrating into the host genome, low production cost,
scalability despite most studies showing less sustained gene expression [16-18]. Non-viral
vectors have been investigated even more aggressively since the death of a patient in a virus-
based gene therapy trial [19] and the occurrence of leukemia following gene therapy of children
with X-linked severe combined immune deficiency using a retroviral gene therapy vector [20].
Previous efforts focused primarily on cationic lipid/DNA complexes frequently composed of
combinations of N-[1-(2,3-dioleyloxy)propyl]-N,N,N-trimethylammonium chloride (DOT‐
MA) [21], dioleoyl phosphatidylethanolamine (DOPE) [22], and dimethylaminoethane-
carbamoyl cholesterol (DC-Chol) [23]. These complexes stabilize incorporated DNA against
physical and enzymatic damage. On the other hand, numerous agents poly(L-lysine), polye‐
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thylenimine (PEI), chitosan, dendrimers etc. have now been extensively investigated as
polymer-based non-viral vector gene delivery systems [24, 25]. The success of these agents is
directly correlated with their ability to overcome issues of low efficiency and inconsistent
preparation that have plagued previous non-viral vector delivery systems.
Among polymeric vectors, the wildly used PEI with appropriate molecular weight can
electrostatically interact with negatively charged phosphate groups of genetic agents to form
particulate polyelectrolyte complexes, which exhibit superior transfection efficiency due to
high buffering capacity [26]. However, high molecular weight of PEI shows high cytotoxicity,
and when further decreasing the molecular weight, both cellular toxicity and transfection
efficiency are decreased [27]. Polyethylene glycol (PEG) was conjugated to PEI to ameliorate
its cell cytotoxicity and develop functionality which limit its clinical application [28-32].
However, free PEI is not easily biodegradable in cellular space, which may remain additional
safety concerns. Therefore, it calls for the development of functional biocompatible materials
with favorable gene transfer efficiency to substitute for PEI [33, 34]. Poly(amino ester)s-based
polymers are a promising class of polymeric gene vector due to their biocompatibility [35-37].
Poly(amino ester)s can be synthesized by Michael addition reaction using functional amines
including a primary and a secondary amine to diacrylate ester [38]. The ease in synthesis and
lack of byproducts make them even more favorable gene vector candidates with biocompati‐
bility and biodegradability properties [38-43].
Here, we are focused on recent progress of different strategies of functionalization of synthetic
biocompatible poly(amino ester)s and the applications of these. The characterization of
physicochemical properties, degradation kinetics, transfection efficiency and toxicity in vitro
and in vivo were covered in this chapter.
2. Poly(amino ester)s-based gene therapy
Poly(amino ester)s are promising and efficient gene delivery vectors due to their high trans‐
fection efficiency and biocompatibility, which were first synthesized by Langer et al. [44-46].
2.1. Poly(amino ester)s synthesis and degradation kinetics
2.1.1. Linear poly(amino ester)s
Varieties of linear poly(amino ester)s are synthesized by Michael addition reaction of small
molecular weight monomers and diacrylate monomers. The Langer group initially investi‐
gated the synthesis of poly(β-amino ester)s via the addition of N,N´-dimethylethylenediamine,
piperazine, and 4,4´-trimethylenedipiperidine to 1,4-butanediol diacrylate as shown in Fig.
1(A). They reported that addition of secondary amines to diacrylate moieties results into
tertiary amines which do not participate in subsequent addition reaction, that otherwise leads
to polymer branching or cross linking.
One of the major merit of poly(β-amino ester)s is degradation. Due to the hydrolysis of the
ester bonds in the polymer backbones, poly(β-amino ester)s can easily degraded. The degra‐
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dation of poly(β-amino ester)s presents a particularly attractive basis for the development of
new polymeric gene carriers for two reasons: firstly, poly(β-amino ester)s degrade into
nontoxic byproducts to increase the safety of gene carrier; secondary, degradation of poly(β-
amino ester)s will increases the transfection efficiency. While complexation of DNA with
cationic polymers is required to compact and protect DNA during early events in the trans‐
fection process, DNA and polymer must ultimately decomplex to allow efficient transcription
[44]. In view of this requirement, degradable poly(β-amino ester)s could play an important
role in “vector unpackaging” events in the cells [44, 47]. As shown in Fig. 1(C), the polymers
degraded more slowly at pH 5.1 than at pH 7.4, and at pH 5.1 each polymer having a half-life
of approximately 7-8 h. In contrast, polymers 1 and 3 [Fig. 1(B)] were completely degraded in
less than 5 h at pH 7.4. These results are consistent with the pH-degradation profiles of other
amine-containing polyesters, such as poly(4-hydroxy-L-proline ester), in which pendant
amine functionalities are hypothesized to act as intramolecular nucleophilic catalysts and
contribute to more rapid degradation at higher pH [44]. The degradation of polymer 2 occurred
more slowly at pH 7.4 than at pH 5.1 due to the incomplete solubility of polymer 2 at pH 7.4
and the resulting heterogeneous nature of the degradation mileu [44].
the degradation mileu [44]. 
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he synthesis of poly(β-amino ester) from butanediol diacrylate and pipera
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different poly(β
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Figure 1. The synthesis of poly(β-amino ester)s from butanediol diacrylate and piperazine (A) and degradation of pol‐
ymer 1-3 at 37 °C at pH 5.1 and 7.4 (B and C). [Source from Ref. [44]].
After that, the same group reported a parallel approach suitable for synthesis of hundreds to
thousands of structurally unique poly(amino ester)s and application of these libraries to rapid
and high throughput identification of new gene delivery agents and structure-function trends
although th y did not report the degradation profiles of poly(amino ester)s in this study [38].
The high throughput method indicated that synthesis of poly(β-amino ester)s are easy to
controlable. The advantage of combinatorial chemistry and automated high throughput
synthesis is that it has revolutionized modern drug discovery by rapid synthesis and evalua‐
tion with greater precision. As shown in Fig. 2, 140 different poly(β-amino ester)s were
synthesized from the 7 diacrylate monomers and 20 amine-based monomers as a screening
library. Polymerization reactions were conducted simultaneously as an array of individually
labeled vials and the reactions were performed in methylene chloride at 45 °C for 5 days.
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Fig. 2. Synthesis of poly(β-amino ester)s. Poly(β-amino ester)s were synthesized 
Figure 2. Synthesis of poly(β-amino ester)s. Poly(β-amino ester)s were synthesized by the conjugate addition of pri‐
mary or bis(secondary amines) to diacrylates using methylene chloride solvent (A) and diacrylate (A-G 7 set) and
amine (1-20) monomers chosen for the synthesis of an initial screening library (B). [Source from Ref. [38]].
Based high throughput methods, in 2003, Anderson synthesiz d over 2,350 poly(β
important role during the synthesis of poly(β
concentration in reaction is desirable to obtain high molecular weight poly(β
nsoluble gel formation [49]. 
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Fig. 3. Synthesis of poly(β-amino ester)s. Poly(β-amino ester)s were synthesized by the 
Figure 3. Synthesis of poly(β-amino ester)s. Poly(β-amino ester)s were synthesized by the conjugate addition of pri‐
mary or bis(secondary amines) to diacrylates using DMSO solvent (A). Amino (numbers) and diacrylate (letters) mono‐
mers (B). [Source from Ref. [48]].
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Based high throughput methods, in 2003, Anderson synthesized over 2,350 poly(β-amino es‐
ter)s as shown in Fig. 3 [48]. Polymerization reactions were performed in 1.6M DMSO at 56
°C for 5 days. Anderson et al. observed that reaction conditions such as optimum tempera‐
ture and solvent play an important role during the synthesis of poly(β-amino ester)s. Even
though maximizing monomer concentration in reaction is desirable to obtain high molecular
weight poly(β-amino ester)s and it leads to insoluble gel formation [49].
Park et al. reported the synthesis of linear poly(amino ester)s from three different molecular
weights of PEG diacrylate and low molecular weight PEI As shown in Fig. 4 [37].
 
(A)   (B) 
Fig. 4. Proposed reaction scheme for copolymer formation (A) and degradation of copolymers (B).
Poly(β
poly(β amino ester)s with PEG diacylate (Mn: 700). This rapid degradation in case of linear poly(β
Figure 4. Proposed reaction scheme for copolymer formation (A) and degradation of copolymers (B). [Source from
Ref. [37]].
It was found that molecular weights of poly(amino ester)s were maintained relatively constant
at about 4kDa during the degradation aftger 72 h regardless of molecular weight of PEG
diacylate. However, half life was observed depending on molecular weight of PEG diacrylate.
Poly(β-amino ester)s composed of PEG diacylate (Mn: 575) showed an half life of 8 h while
that of 25 h for poly(β-amino ester)s with PEG diacylate (Mn: 700). This rapid degradation in
case of linear poly(β-amino ester)s is plausible as even few cleavages may reduce chain length
rapidly with quick drop in molecular weight [37].
2.1.2. Branched poly(amino ester)s
Liu et al. synthesized the branched poly(amino ester)s by the polymerization of 1-(2-amino‐
ethyl)piperazine (AEPZ) with 1,4-butanediol diacrylate (BDA), which was carried out by
adding BDA dropwise to an equimolar solution of AEPZ in chloroform at 45 °C as shown in
Fig. 5 [50]. After the polymerization was performed for around 72 h, a water-soluble polymer,
BDA-AEPZ, was obtained by precipitating the solution into acetone containing HCl. The
molecular weight of BDA-AEPZ was around 5126 with a polydispersity index of 1.52 as
determined by GPC.
Novel Gene Therapy Approaches380
Poly(β
poly(β amino ester)s with PEG diacylate (Mn: 700). This rapid degradation in case of linear poly(β
BDA-AEPZ was around 5126 with a polydispersity index of 1.52 as determined by GPC. 
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Fig. 5. Possible routes of the Michael addition polymerization of trifunctional amine monomers and 
Figure 5. Possible routes of the Michael addition polymerization of trifunctional amine monomers and diacrylates (A)
and the structure of poly(amino ester)s obtained and enlarged 13C-NMR (INVGATE) spectrum of methylene carbons
attached to the hydrochloride salts of amines in BDA-AEPZ (B). [Source from Ref. [50]].
The polymerization of AEPZ with diacylate monomers was reported but branched poly(amino
ester)s with primary, secondary and tertiary amines were supposed to be formed based on un-
solidified experimental conditions, suggesting that secondary amines are more reactive than
primary ones in case of trifunctional amines [50]. Wu et al. also synthesized protonated
hyperbranched poly(amino ester)s and characterized as gene delivery carriers as shown in
Fig. 6(A) [51]. It was found that all these hyperbranched poly(amino ester)s degraded in a
controlled manner within 50 days and it was speculated that this phenomenon may be due to
the lesser water accessibility of the ester groups in hyperbranched sturctures [Fig. 6(B)].
 
(A)   (B) 
Fig. 6. Structure of linear and hyperbranched poly(amino ester)s obtained via Michael addition
Cho’s group also reported the synthesis of branch poly(amino ester)s by Michael addition, based on 
Figure 6. Structure of linear and hyperbranched poly(amino ester)s obtained via Michael addition polymerization of
trifunctional amines with diacrylates and triacrylates (A) and comparison of the hydrolysis profiles of protonated hy‐
perbranched poly(BDA2-AEPZ1)-MPZ, hyperbranched poly(TMPTA1-AEPZ2), and linear poly(BDA-AEPZ) in aqueous
solutions (B). [Source from Ref. [51]].
Cho’s group also reported the synthesis of branch poly(amino ester)s by Michael addition,
based on hydrophobic polycaprolactone diacrylate and low molecular weight PEI [Fig. 7(A)]
[40]. It was simply an indication of application of ester linkage which supports the easy
degradation leaving nontoxic building blocks, thereby increased transfection efficiency and
reduced cytotoxicity. The branched poly(amino ester)s showed controlled degradation with
the half life of 4-4.5 days as shown in Fig. 7(B).
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Cho’s group also reported the synthesis of branch poly(amino ester)s by Michael addition, based on 
in Fig. 7(B). 
(A)   (B) 
Fig. 7. The synthetic scheme of PEA by Michael addition (A) and degradation of PEAs (PCL/PEI-1.2 
Figure 7. The synthetic scheme of PEAs by Michael addition (A) and degradation of PEAs (PCL/PEI-1.2 and PCL/
PEI-1.8) (B). [Source from Ref. [40]].
Same group also reported another degradable branched poly(amino ester)s based on polox‐
amer diacrylate and low molecular weight PEI [52]. These hyperbranched poly(amino ester)s
can be easily synthesized by Michael type addition reaction between poloxamer diacrylate and
low molecular weight PEI [Fig. 8(A)] and the hyperbranched poly(amino ester)s showed slow
degradation at physiological conditions which was greatly dependent on hydrophilicity of
poloxamer [Fig. 8(B)].
(A)  (B) 






Figure 8. Synthetic scheme of PEA by Michael addition reaction (A) and degradation of PEAs (B). PEAs were dissolved
in 0.1 M PBS, and incubated at 37 °C with 100 rpm. [Source from Ref. [52]].
All together, poly(amino ester)s can be easily synthesized by Michael type addition reaction
and showed good degradation profiles due to the hydrolysis of the ester bonds in the polymer
backbones.
2.2. Characterization of po (amino ester)s/DNA complexes
2.2.1. DNA condensation and protection
One prerequisite of a polymeric gene carrier is DNA condensation [53]. Polycation-mediated
gene delivery is based on the electrostatic interactions between the positive charged polycation
and negatively charged phosphate groups of DNA [32]. As shown in Fig. 9(A), retardation of
DNA migration begins at poly(β-amino ester)s/DNA ratios as low as 0.1:1 (w/w) and migration
is completely retarded at poly(β-amino ester)s/DNA ratios above 5:1 (w/w) [34]. Condensation
protects the DNA from degradation by nucleases, and the compact particles can be taken up
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by cells via natural processes such as adsorptive endocytosis, pinocytosis and phagocytosis
[32]. DNA in the complexes was protected from nuclease attack whereas the naked DNA was
degraded. This result suggests that intact DNA could be delivered by poly(β-amino ester)s
into cells without degradation [Fig. 9(B)] [34].
Figure 9. DNA condensation and protection study. Agarose gel electrophoresis of poly(β-amino ester)s (GPT–
SPE)/DNA complexes at various weight ratios (A) and DNA protection and release assay (B). [Source from Ref. [34]].
2.2.2. Particle sizes and surface charges of poly(amino ester)s/DNA complexes
Surface properties, such as particle size and surface charge of the complex, are necessary to
assure its uptake by cells [53]. In particular, the particle size of a complex is an important factor
that influences the access and passage of the complex through the targeting site. Successful
gene carrier depends on its ability to condense negatively charged DNA into nanosized
particles with positive charges so as to enter into the cells [54]. Compact particles of small size
are usually obtained only at higher N/P ratios, resulting in complexes with a strong positive
Poly(amino ester)s-Based Polymeric Gene Carriers in Cancer Gene Therapy
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net charge. For most cell types, the poly(amino ester)s/DNA complexes size requirement is on
the order of 200 nm or less [55]. As shown in Fig. 10(A), poly(β-amino ester)s formed complexes
with diameters in the range of 50-150 nm at DNA/polymer ratios above 1:2. A positive surface
charge of polyplexes is necessary for binding to anionic cell surfaces, which consequently
facilitates uptake by the cell [30, 56]. The surface charge of poly(β-amino ester)s/DNA com‐
plexes has been examined in terms of ζ-potential. The ζ-potentials for complexes were on the
order of +10 to +15 mV at DNA/polymer ratios above 1:1, and the complexes did not aggregate
extensively over an 18h period as shown in Fig. 10(B).
poly(β
poly(β amino ester)s/DNA complexes has been examined in terms of ζ potential. The ζ
 
 (A)     (B) 
Fig. 10. Average effective diameters (A) and ζ-potentials (B) of DNA/polymer complexes formed 
Luc plasmid and poly(βFigure 10. Average effective diameters (A) and ζ-potentials (B) of DNA/polymer complexes formed from pCMV-Luc
plasmid and poly(β-amino ester)s (polymer 3) (Mn = 31000) as a function of polymer concentration. [Source from Ref.
[44]].
2.3. Toxicity and transfection considerations of poly(amino ester)s/DNA complexes in vitro
Safe and efficient delivery of genes is critical for the successful application of gene therapy. In
fact, it is the only major obstacle in the expansion of gene therapy from bench to beside. Many
vectors with high transfection efficiency show high toxicity while vectors with low toxicity are
poor in transfecting cells. Optimum balance between these two parameters is a key to the
success in gene therapy [57-59]. As biodegradable polymers are designed to contain a combi‐
nation of various functional components, it is likely that engineered systems for non-viral gene
delivery, especially with the application of biodegradable ester linkage will eventually be
constructed. This biodegradable linkage approach to vector development is giving way to a
safety profile where low molecular weight amine contain monomers are couples with acylate
linkers to yield high molecular weight poly(amino ester)s with reduced toxicity and enhanced
transfection efficiency.
Jere et al. evaluated cytotoxicity of mini-library of poly(amino ester)s in 293T and HeLa cells
by MTS assay [59]. In order to measure maximum possible cytotoxicity, poly(amino ester)s
were administered in increasing concentrations to 293T cells as shown in Figs. 11(A) and (B).
In both cell lines, poly(amino ester)s obtained from R106 to R113 exhibited very high cytotox‐
icity which further increased with increase in weight ratios, while poly(amino ester)s obtained
from R114, R115 and R116 showed good cell viability at lower ratios but significant cytotoxicity
at higher weight ratios. Excellent cell viability and uniform transfection pattern were observed
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with poly(amino ester)s obtained from R117 to R121. Slight cytotoxicity was observed at higher
mass ratios (90:1 and 110:1) (viability above 80% in all ratios) indicating that cytotoxicity was
highly sensitive to monomer ratio and varied drastically even with small change in monomer
concentration. It was reported that the cytotoxicity of cationic polymers is probably caused by
polymer aggregation on cell surfaces, impairing important membrane functions. Also, the
cationic polymers may interfere with critical intracellular processes of cells: in particular, the
primary amine was reported to disrupt PKC function through disturbance of protein kinase
activity [60, 61]. On the other hands, in 293T cells, poly(amino ester)s obtained from R106 to
R113 showed some transfection at lower weight ratios but it was suddenly decreased with
increased weight ratios which may be because of low cell viability at these ratios [Fig. 11(C)].
Poly(amino ester)s obtained from R114 to R119 showed intermediate transfection while
poly(amino ester)s obtained from R120 and R121 gave good transfection. However, in HeLa
cells slightly different transfection pattern was observed as shown in Fig. 11(D)]. Poly(amino
ester)s obtained from R106 to R115 failed to give significant transfection. On the other hand,
poly(amino ester)s obtained from R116 to R119 showed intermediate transfection which was
slowly increased from R116 to R119. Transfection was highest with poly(amino ester)s
obtained from R120 and R121 and it was increased with increasing weight ratios till 90:1 after
that it again decreased due to increased cytotoxicity. It was also reported that in addition to
factors such as chemical structure and polymer molecular weight, either amine or acrylate
terminated also plays a significant role in determining transfection efficiency of poly(amino
ester)s [46]. Excess of amine monomers results into amine terminated polymer which effec‐
tively binds with cell membrane and promotes its uptake whereas acrylate terminated




Fig. 11. Cytotoxicity of PAEs at various concentrations in 293T cell line (A) and HeLa cell line (B); 
Figure 11. Cytotoxicity of PAEs at various concentrations in 293T cell line (A) and HeLa cell line (B); and transfection
efficiency of PAE/DNA complexes in serum free-media at various mass ratios in 293T cells (C) and HeLa cells (D).
[Source from Ref. [59]].
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2.4. Toxicity and transfection considerations of poly(amino ester)s/DNA complexes in
vivo
Intravenous administration as one of the most commonly used methods in gene therapy
area even most  gene therapy vectors,  as  well  as  other  biomolecules  and potential  engi‐
neered  drugs,  has  short  elimination  half-lives  due  to  the  serum  proteins  in  the  blood
stream. In vivo transfection efficiency of the poly(amino ester)s was studied after intrave‐
nous administration into mice [62]. As shown in Fig. 12, the quantity of luciferase was de‐
termined in lung, liver, spleen, kidney and heart after 24 h intravenous administration of
polymer/DNA complexes. Fig. 12 shows luciferase gene expression in various mouse or‐
gans after intravenous administration of the polymer/DNA complexes via the tail vein. As
shown in Fig. 12, injection of polymer/DNA complexes resulted in transfection primarily
in the lung which is in agreement with previous results [63, 64].  Verbaan et al.  suggest‐
ed two mechanisms regarding this  phenomenon of  predominant  gene expression in the
lung; firstly, because the lung is the first organ encountered by polyplexes after tail vein
injection,  the  positively  charged polyplexes  may electrostatically  interact  with  the  nega‐
tively charged membranes of the endothelial cells in the lung, secondly, the physical trap‐
ping of large aggregates formed by the interaction of polyplexes with blood components
like  serum  proteins  and  erythrocytes  [63,  64].  Also,  the  poly(amino  ester)s/DNA  com‐
plexes showed the highest  transfection activity in the lung regardless of  N/P ratio.  This
may be caused by the positive charge of the poly(amino ester)s/DNA complexes like PEI
25K/DNA  complexes.  In  contrast  to  PEI  25K/DNA  complexes,  the  poly(amino
ester)s/DNA complexes had high transfection in the liver because the liver is the main or‐
gan for gene accumulation and subsequent degradation [62]. Plank et al. reported that op‐
sonization  of  the  polyplexes  led  to  a  rapid  clearance  by  the  mononuclear  phagocytic
system (MPS) [65].  Uptake by the MPS would be in agreement with the observed liver
and spleen accumulations. In addition, the presence of discontinuous or fenestrated endo‐
thelia in the vascularization of the liver and spleen may facilitate the gene accumulation
in these tissues [66].  The poly(amino ester)s/DNA complexes showed higher transfection
efficiency  than  golden  standard  PEI  25K/DNA ones,  and the  luciferase  activity  was  in‐
creased in all organs except kidney with increase of N/P ratio indicating that poly(amino
ester)s/DNA complexes function efficiently after intravenous administration.
Implantable infusion pumps have been developed as an one of therapy methods for a num‐
ber of diseases, and there has been remarkable progress in endoscopic and laparoscopic sur‐
gical techniques. This progress in surgical techniques and devices could make
intraperitoneal administration a conventional and feasible approach for future clinical appli‐
cations [67]. Intraperitoneal gene delivery may provide a strategy for the treatment of a vari‐
ety of diseases, including cancer. Zugates et al. synthesized parallel end-modification of
poly(β-amino ester)s by the conjugate addition of amines to diacrylate monomers as shown
in Fig. 13 [68].
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Figure 12. Tissue distribution of poly(amino ester)s/DNA (gWIZ-Luc) complexes administered by intravenous injection
and inhalation at various N/P ratios. (∗p < 0.1; ∗∗p < 0.05, Student’s t-test, two-tailed). [Source from Ref. [62]].
(A)   (B) 
Fig. 13. Intraperitoneal gene delivery in mice (A). (a) Whole-body optical images of luciferase 
show the highest expression obtained for each polymer. The control mouse was injected with 120 μl 
PEI) (black). n ≥ 3 for each 





Figure 13. Intraperitoneal gene delivery in mice (A). (a) Whole-body optical images of luciferase expression in FVB/J
mice 6 hours after intraperitoneal injection of polymer/DNA complexes. Images show the highest expression obtained
for each polymer. The control mouse was injected with 120 μl of 50 mM NaAc buffer, pH 5.2. Pseudocolor images
representing emitted bioluminescence are superimposed over grayscale images. Relative light units (RLUs)/pixel are
indicated in the color scale bar on the left. (b) Quantification of whole-body luciferase expression at various times af‐
ter intraperitoneal injection of C32- (hatched) and C32-117-delivered (solid) DNA. Statistically significant differences
between C32 and C32-117 at a given time point are indicated. n = 4 for each treatment group. *P <0.05; **P < 0.01;
***P < 0.001. Organ distribution of gene expression (B). Quantification of luciferase expression in whole body and in‐
dividual organs 6 hours after intraperitoneal injection of polymer/DNA complexes in FVB/J mice. Results are expressed
as mean transfection levels (± SD) for a buffer control (white), C32-103 (yellow), C32-116 (red), C32-117 (green),
C32-122 (blue), C32 (pink), and jet-polyethylenimine (jet-PEI) (black). n ≥ 3 for each treatment group. [Source from
Ref. [68]].
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High transfection levels were observed after intraperitoneal injection of polymer/DNA
complexes. End-modified polymers resulted in whole-body reporter protein expression more
than an order-of magnitude higher than that for jet-PEI. They also outperformed the best
poly(β-amino ester)s synthesized to date, C32, with overall expression levels 4- to 12-fold
higher. They found that sustained expression past 1 week both with modified C32 and with
C32, but modified C32 was expressed at significantly higher levels, reflecting its enhanced
delivery capabilities. This effect was most evident between the C32-116 and C32-117 polymers,
where the latter displayed 5- to 65-fold higher delivery to the bladder, spleen, liver, and kidney.
The only difference between these two diaminopropane end-capping reagents is the ethyl
versus dimethyl branching.
poly(β
 (A)    (B) 
Fig. 14. (A) In vivo analysis after aerosol administration to lungs. Two days after exposure, mice
μm). (B) Therapeutic efficiency of GPT–
–
–
circle indicates the incidence in the lungs (magnification: 200×, scale bar represents 50 μm). (E) 
–
Figure 14. A) In vivo analysis after aerosol administration to lungs. Two days after exposure, mice were sacrificed and
lungs were collected for the detection of GFP signal and Hematoxylin & Eosin staining. (A) Transfection efficiency
study: GFP expression analysis (mag ification: 200×). B) Lung histopathology study: Hematoxylin & Eosin staining
(magnification: 200×, scale bar represents 50 μm). (B) Therapeutic efficiency of GPT–SPE as aerosol gene delivery carri‐
er in lung tumor bearing K-rasLA1 mice: aerosol delivery of GPT–SPE/Akt1 shRNA significantly inhibited lung tumor
numbers: (A) Lungs showing numerous visible lesions (red circle represents tumor tissues). (B) Total tumor numbers (n
= 4, *p < 0.05, **p < 0.01). (C) Tumor size over 1 mm tumor numbers (n = 4, *p < 0.05, **p < 0.01, ***p < 0.001). Aero‐
sol delivery of GPT–SPE/Akt1 shRNA significantly suppressed lung tumor progression through the Akt signaling path‐
way. (D) Histopathological characteristics. Red circle indicates the incidence in the lungs (magnification: 200×, scale
bar represents 50 μm). (E) Western blot analysis of Akt1 protein expression in the lungs and bands-of-interest were
further analyzed by densitometer (n = 4, **p < 0.01, ***p < 0.001).
One of the most non-invasive approaches to drug/gene delivery is via inhalation. Gene ther‐
apy to the lung can potentially be exploited for the treatment of both genetic and acquired
diseases. However, any therapeutic approach for the respiratory tract must take into account
the heterogeneity of the cellular targets in the lung: epithelial cells, alveolar cells, vascular
cells, serous cells in the sub-mucosal glands and a number of other cell types [69]. Our
group developed spermine-based biocompatible poly(β-amino ester)s as an aerosol delivery
gene carrier [34]. As shown in Fig. 14 (A-A), GFP signal was dominant in the lungs with
GPT–SPE/GFP complexes-exposed group compared to the control and naked GFP-exposed
groups. No necrosis, degeneration, metaplasia, anaplasia in pneumocytes, atelectasis, or em‐
physema were detected [Fig. 14 (A-B)]. These results indicate that GPT–SPE functions safely
and efficiently in aerosol delivery system. Significant anticancer effects of GPT–SPE/Akt1
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shRNA complexes in the lungs through aerosol inhalation were observed in lung tumor
bearing K-rasLA1 mice [Fig. 14 (B)] without toxicity [Table 2]. These result indicating that
poly(β-amino ester)s (GPT-SPE) could be a safe and efficient gene carrier in aerosol-adminis‐
tered lung cancer gene therapy.
CBC, complete blood count; WBC, white blood cell; RBC, red blood cell; HGB, hemoglobin; HCT, hematocrit; MCV, mean
cell volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; CHCM, mean
cell hemoglobin concentration; RDW, red cell distribution width; PLT, platelets; MPV, mean platelet volume; PDW, platelet
distribution width; PCT, plateletcrit; MPC, mean platelet component; MPM, mean platelet mass; Large Pit, large platelets.
Table 2. Toxicological analysis. Blood samples were collected for routine examination and to assess the potential
toxicity of GTP–SPE. [Source from Ref. [34]].
2.5. Targeting considerations
Targeting confers another important criterion in gene delivery. To increase specificity and
safety of gene therapy further, the expression of the therapeutic gene needs to be tightly
controlled within the target tissue. Targeted gene expression has been analyzed using tissue-
specific promoters (breast-, prostate-, and melanoma-specific promoters) and disease-specific
promoters (carcinoembryonic antigen, HER-2/neu, Myc-Max response elements, DF3/MUC).
Alternatively, expression could be regulated externally with the use of radiation-induced
promoters or tetracycline-responsive elements [70]. Recently, Arote et al. coupled folic acid
moiety to the poly(amino ester)s backbone using PEG (MW: 5000 Da) as a linker for targeting
of folate receptor, a tumor associated glycosylphosphatidylinositol anchored protein [71]. As
shown in Fig. 15, folate-PEG-poly(amino ester)s (FP-PAEs) showed marked anti-tumor activity
against folate receptor-positive human KB tumors in nude mice with no evidence of toxicity
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during and after therapy using the TAM67 gene. Anti-tumor activity with PAEs without folic
acid moiety (PEGylated-PAEs, P-PAEs) proved ineffective against a xenograft mice model than
that with FP-PAEs at the same dose, suggesting that FP-PAEs is a highly effective gene carrier
capable of producing a therapeutic benefit in a xenograft mice model without any signs of
toxicity.
  
Fig. 17. Effect of FP-PEA/TAM67 complexes on tumor growth. The tumor volume in BALB/c mic
ification, X 400; bar = 20 μm). (D) Comparison of phospho
20 μm). (I) Comparison of PCNA labeling index in tumors. PCNA positive staining was determined 
Figure 15. Effect of FP-PEAs/TAM67 complexes on tumor growth. The tumor volume in BALB/c mice bearing KB cells
was recorded every 3 d. Tumor tissue homogenates were subjected to western blot analysis. Blots were probed with
antibodies as indicated. (A) Expression level of phospho-c-Jun. (B) The bands-of-interest were further analyzed by den‐
sitometer. (C) Immunohistochemic l analysis of phospho-c-Ju  in t e tumors. Dark brown color indicates the phos‐
pho-c-Jun expression (magnification, X 400; bar = 20 μm). (D) Comparison of phospho-c-Jun labeling index in tumors.
phospho-c-Jun positive staining was determined by counting 10 randomly chosen fields per section, determining the
percentage of DAB positive cell per 100 cells at X 400 magnification. (E) Suppression of tumor growth by FP-PEAs/
TAM67 complexes (F) Expression level of PCNA. (G) The bands-of-interest were further analyzed by densitometer. (H)
Immunohistochemical analysis of PCNA in the tumors. Dark brown color indicates the PCNA expression (magnifica‐
tion, X 400; bar = 20 μm). (I) Comparison of PCNA labeling index in tumors. PCNA positive staining was determined by
counting 10 randomly chosen fields per section, determining the percentage of DAB positive cell per 100 cells at X
400 magnification. (*, P < 0.05; **, P < 0.01 compared with control; #, P < 0.05; ##, p < 0.01 compared with vector
control; n = 4). [Source from Ref. [71]].
3. Conclusion
Gene therapy shows tremendous promise for a broad spectrum of clinical applications.
Development of a safe and efficient gene delivery system is one of the main challenges to be
solved before this strategy can be adopted for routine use in clinical trails. As a degradable
cationic polymeric gene carrier, poly(amino ester)s comprise many desirable properties in the
context of gene delivery, including condensation of DNA into nanoscale-size particles and
protects DNA from endogenous nucleases and efficiently deliver DNA with low toxicity. The
need for clinical application of poly(amino ester)s, more comprehensive preclinical investiga‐
tions such as exact quality control (QC) of polymer, pharmacokinetics and toxicological studies
should be performed.
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